Targeting Heat Shock Protein 90 for the Treatment of Malignant Pheochromocytoma

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Giubellino, Alessio ^a   Sourbier, Carole ^b   Lee, Min Jung ^b   Scroggins, Brad ^b   Bullova, Petra ^a   Landau, Michael ^b   Ying, Weiwen ^c   Neckers, Len ^b   Trepel, Jane B ^b   Pacak, Karel ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Synta Pharmaceuticals Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANETESPIB; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; TANESPIMYCIN;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PHEOCHROMOCYTOMA; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; SURVIVAL TIME; TUMOR XENOGRAFT;

ADRENAL GLAND NEOPLASMS; ADRENAL GLANDS; ANIMALS; APOPTOSIS; BENZOQUINONES; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MICE; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PHEOCHROMOCYTOMA; RATS; TRIAZOLES;

EID: 84874009582     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056083     Document Type: Article

References (51)

1. Lenders JW, Eisenhofer G, Mannelli M, Pacak K, (2005) Phaeochromocytoma. Lancet 366: 665-675.
2. Gimenez-Roqueplo AP, Dahia PL, Robledo M, (2012) An update on the genetics of paraganglioma, pheochromocytoma, and associated hereditary syndromes. Horm Metab Res 44: 328-333.
3. Favier J, Briere JJ, Strompf L, Amar L, Filali M, et al. (2005) Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Horm Res 63: 171-179.
4. Benn DE, Croxson MS, Tucker K, Bambach CP, Richardson AL, et al. (2003) Novel succinate dehydrogenase subunit B (SDHB) mutations in familial phaeochromocytomas and paragangliomas, but an absence of somatic SDHB mutations in sporadic phaeochromocytomas. Oncogene 22: 1358-1364.
5. Buffet A, Venisse A, Nau V, Roncellin I, Boccio V, et al. (2012) A decade (2001-2010) of genetic testing for pheochromocytoma and paraganglioma. Horm Metab Res 44: 359-366.
6. Weber A, Hoffmann MM, Neumann HP, Erlic Z (2012) Somatic Mutation Analysis of the SDHB, SDHC, SDHD, and RET Genes in the Clinical Assessment of Sporadic and Hereditary Pheochromocytoma. Horm Cancer.
7. Jimenez C, Cabanillas ME, Santarpia L, Jonasch E, Kyle KL, et al. (2009) Use of the tyrosine kinase inhibitor sunitinib in a patient with von Hippel-Lindau disease: targeting angiogenic factors in pheochromocytoma and other von Hippel-Lindau disease-related tumors. J Clin Endocrinol Metab 94: 386-391.
8. Nolting S, Grossman AB, (2012) Signaling pathways in pheochromocytomas and paragangliomas: prospects for future therapies. Endocr Pathol 23: 21-33.
9. Druce MR, Kaltsas GA, Fraenkel M, Gross DJ, Grossman AB, (2009) Novel and evolving therapies in the treatment of malignant phaeochromocytoma: experience with the mTOR inhibitor everolimus (RAD001). Horm Metab Res 41: 697-702.
10. Taipale M, Jarosz DF, Lindquist S, (2010) HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 11: 515-528.
11. Trepel J, Mollapour M, Giaccone G, Neckers L, (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10: 537-549.
12. Boltze C, Mundschenk J, Unger N, Schneider-Stock R, Peters B, et al. (2003) Expression profile of the telomeric complex discriminates between benign and malignant pheochromocytoma. J Clin Endocrinol Metab 88: 4280-4286.
13. Pacak K, (2011) Phaeochromocytoma: a catecholamine and oxidative stress disorder. Endocr Regul 45: 65-90.
14. Grogan RH, Mitmaker EJ, Duh QY, (2011) Changing paradigms in the treatment of malignant pheochromocytoma. Cancer Control 18: 104-112.
15. Kim YS, Alarcon SV, Lee S, Lee MJ, Giaccone G, et al. (2009) Update on Hsp90 inhibitors in clinical trial. Curr Top Med Chem 9: 1479-1492.
16. Jhaveri K, Taldone T, Modi S, Chiosis G, (2012) Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta 1823: 742-755.
17. Taldone T, Sun W, Chiosis G, (2009) Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 17: 2225-2235.
18. Neckers L, Workman P, (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64-76.
19. Wang Y, Trepel JB, Neckers LM, Giaccone G, (2010) STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs 11: 1466-1476.
20. Ying W, Du Z, Sun L, Foley KP, Proia DA, et al. (2012) Ganetespib, a unique triazolone-containing Hsp90 inhibitor, exhibits potent antitumor activity and a superior safety profile for cancer therapy. Mol Cancer Ther 11: 475-484.
21. Proia DA, Foley KP, Korbut T, Sang J, Smith D, et al. (2011) Multifaceted intervention by the Hsp90 inhibitor ganetespib (STA-9090) in cancer cells with activated JAK/STAT signaling. PLoS One 6: e18552.
22. Giubellino A, Woldemichael GM, Sourbier C, Lizak MJ, Powers JF, et al. (2012) Characterization of two mouse models of metastatic pheochromocytoma using bioluminescence imaging. Cancer Lett 316: 46-52.
23. Powers JF, Evinger MJ, Tsokas P, Bedri S, Alroy J, et al. (2000) Pheochromocytoma cell lines from heterozygous neurofibromatosis knockout mice. Cell Tissue Res 302: 309-320.
24. Martiniova L, Lai EW, Elkahloun AG, Abu-Asab M, Wickremasinghe A, et al. (2009) Characterization of an animal model of aggressive metastatic pheochromocytoma linked to a specific gene signature. Clin Exp Metastasis 26: 239-250.
25. Greene LA, Tischler AS, (1976) Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc Natl Acad Sci U S A 73: 2424-2428.
26. Isaacs JS, Jung YJ, Mimnaugh EG, Martinez A, Cuttitta F, et al. (2002) Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J Biol Chem 277: 29936-29944.
27. Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R, (1998) Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. Cell 94: 471-480.
28. Zhang H, Chung D, Yang YC, Neely L, Tsurumoto S, et al. (2006) Identification of new biomarkers for clinical trials of Hsp90 inhibitors. Mol Cancer Ther 5: 1256-1264.
29. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, et al. (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25: 5410-5417.
30. Tischler AS, Powers JF, Alroy J, (2004) Animal models of pheochromocytoma. Histol Histopathol 19: 883-895.
31. Cascon A, Tennant DA, (2012) From transcriptional profiling to tumor biology in pheochromocytoma and paraganglioma. Endocr Pathol 23: 15-20.
32. Kaelin WG Jr, (2008) The von Hippel-Lindau tumour suppressor protein: O2 sensing and cancer. Nat Rev Cancer 8: 865-873.
33. Schlisio S, Kenchappa RS, Vredeveld LC, George RE, Stewart R, et al. (2008) The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 22: 884-893.
34. Favier J, Igaz P, Burnichon N, Amar L, Libe R, et al. (2012) Rationale for anti-angiogenic therapy in pheochromocytoma and paraganglioma. Endocr Pathol 23: 34-42.
35. Jyung RW, LeClair EE, Bernat RA, Kang TS, Ung F, et al. (2000) Expression of angiogenic growth factors in paragangliomas. Laryngoscope 110: 161-167.
36. Brieger J, Bedavanija A, Gosepath J, Maurer J, Mann WJ, (2005) Vascular endothelial growth factor expression, vascularization and proliferation in paragangliomas. ORL J Otorhinolaryngol Relat Spec 67: 119-124.
37. Favier J, Plouin PF, Corvol P, Gasc JM, (2002) Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 161: 1235-1246.
38. Rooijens PP, de Krijger RR, Bonjer HJ, van der Ham F, Nigg AL, et al. (2004) The significance of angiogenesis in malignant pheochromocytomas. Endocr Pathol 15: 39-45.
39. Lopez-Jimenez E, Gomez-Lopez G, Leandro-Garcia LJ, Munoz I, Schiavi F, et al. (2010) Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. Mol Endocrinol 24: 2382-2391.
40. Dezwaan DC, Freeman BC, (2008) HSP90: the Rosetta stone for cellular protein dynamics? Cell Cycle 7: 1006-1012.
41. Neckers L, Tsutsumi S, Mollapour M, (2009) Visualizing the twists and turns of a molecular chaperone. Nat Struct Mol Biol 16: 235-236.
42. Neckers L, Mollapour M, Tsutsumi S, (2009) The complex dance of the molecular chaperone Hsp90. Trends Biochem Sci 34: 223-226.
43. Schulte TW, Blagosklonny MV, Ingui C, Neckers L, (1995) Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 270: 24585-24588.
44. Basso AD, Solit DB, Chiosis G, Giri B, Tsichlis P, et al. (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J Biol Chem 277: 39858-39866.
45. Lai EW, Rodriguez OC, Aventian M, Cromelin C, Fricke ST, et al. (2007) ErbB-2 induces bilateral adrenal pheochromocytoma formation in mice. Cell Cycle 6: 1946-1950.
46. Engelman JA, Settleman J, (2008) Acquired resistance to tyrosine kinase inhibitors during cancer therapy. Curr Opin Genet Dev 18: 73-79.
47. Bishop SC, Burlison JA, Blagg BS, (2007) Hsp90: a novel target for the disruption of multiple signaling cascades. Curr Cancer Drug Targets 7: 369-388.
48. Xu W, Neckers L, (2007) Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 13: 1625-1629.
49. Banerji U, (2009) Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res 15: 9-14.
50. Rajan A, Kelly RJ, Trepel JB, Kim YS, Alarcon SV, et al. (2011) A phase I study of PF-04929113 (SNX-5422), an orally bioavailable heat shock protein 90 inhibitor, in patients with refractory solid tumor malignancies and lymphomas. Clin Cancer Res 17: 6831-6839.
51. Korpershoek E, Pacak K, Martiniova L, (2012) Murine models and cell lines for the investigation of pheochromocytoma: applications for future therapies? Endocr Pathol 23: 43-54.